CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study
DOI 10.1055/s-0034-1385996
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, T Göser, AW Lohse, T Berg, P Galle, H Wedemeyer, G Gerken, S Mauss, R Thimme, P Pang, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: The Phase 3 ION-1 study is evaluating whether the fixed-dose combination of sofosbuvir 400 mg/ledipasvir 90 mg (SOF/LDV) can effectively treat a population of treatment-naïve patients with genotype 1 HCV-infection and to determine if ribavirin (RBV) or longer treatment duration is required to achieve a high SVR rate. Methods: HCV-infected patients in the United States and Europe were randomized…
Zitieren
Zitierempfehlung
P Buggisch, T Göser, AW Lohse, T Berg, P Galle, H Wedemeyer, G Gerken, S Mauss, R Thimme, P Pang, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, S Zeuzem (2014) All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0034-1385996
Mit CareLit weiterarbeiten